CDR-Life is at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting!
Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs:
• CDR404 – MAGE-A4+ solid tumors
• CDR609 – First-in-class LGR5-targeted TCE

Proud to have our CBO Sarah Holland chair the Pharma Strategy & Dealmaking Panel at the #Sachs_BEF alongside leaders from @abbvie.bsky.social, Covington & Burling LLP, GSK, Merck, Novartis and @sobibird.bsky.social

Aug 25–29: Our CBO Sarah Holland joins Biotechgate Digital Partnering to discuss partnering our T cell engagers for solid tumors & autoimmune diseases, and how our M-gager® platform is advancing a highly specific clinical pipeline.

Still spots open—reach out to connect!

Meet Romina Doerig, Developability Expert at CDR-Life.
She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic.

Her motto: take the chance—you’ll regret the ones you don’t.
Fun fact: she never visits the same place twice!

CDR-Life announces CDR609, a novel T-cell engager targeting LGR5—a highly tumor-specific antigen broadly expressed across common solid tumors including colorectal and pancreatic cancer.

Built on our M-gager® platform. IND-enabling studies planned for H2 2025.

Details: bit.ly/46dO0ne

CEO Christian Leisner talks targeting “clean” cancer antigens with T-cell engagers, early CDR404 data, expansion into autoimmunity (CDR111), Boehringer deal & why Switzerland is ideal for biotech. Full PharmaBoardroom interview:
pharmaboardroom.com/interviews/c...

Our CEO Christian Leisner will be at the Jefferies Global Healthcare Conference in NYC next week, sharing how our M-gager® platform is redefining T cell engager precision in solid tumors & autoimmune disease. Connect to learn more. #JefferiesHealthcare

CDR-Life CBO Sarah Holland will be at #BIO2025 in Boston, June 16–19. Learn about our M-gager® platform + T cell engager therapies for cancer & autoimmune disease. Want to meet? Drop us a note.

We’re excited to welcome Pascal Touchon to CDR-Life’s Board. With 40 years in biopharma, including roles at Atara, Ipsen & Novartis, Pascal brings strategic insight, deep industry knowledge and a wide global network —perfectly timed as our first T cell engager progresses in Phase 1. bit.ly/4jqKlpf

A big first for CDR-Life! Our team took on the legendary Sola Stafette relay in Zurich with incredible spirit — on the course and cheering from the sidelines. Still buzzing from the energy, teamwork & fun. Here’s to many more finish lines!
#TeamCDRLife #SolaStafette

#AACR2025 recap:
•CDR404 (MAGE-A4): Strong activity in "cold" tumors, less T-cell exhaustion, early signs of anti-tumor effect in Ph1
•CDR505 (KK-LC-1): 1st TCE for KK-LC-1+ tumors in HLA-A*01:01 pts—potent, precise, promising
Posters: www.cdr-life.com/our-science/...

On #ClinicalTrialsDay, we honor the patients, clinicians & researchers driving progress. Our Phase 1 trial of CDR404 — a bispecific T-cell engager targeting MAGE-A4+ tumors — is a key step in advancing precision immunotherapy. Thank you for making it possible.

Chicago bound! The CDR-Life team is heading to #ASCO25 to discuss our M-gager® platform and lead program CDR404, now in Phase 1 for MAGE-A4+ tumors as well as CDR609, our first program targeting a highly cancer specific surface antigen widely expressed in common tumor types. Let’s connect!!

CDR-Life is at #BIOEquityEurope! CEO Christian Leisner is sharing how our M-gager® T cell engagers are advancing solid tumor & autoimmune therapies. Meet in person or join virtual partnering next week to connect. #TCellEngagers

Join CDR-Life at Swiss Biotech Day (May 5–6)! Hear from our VP Clare Price, and meet CEO Christian Leisner, and CBO Sarah Holland, as they showcase how M-gager® is transforming T cell engager therapy. Let’s connect! #SwissBiotechDay #immunotherapy

#InternationalWomensDay! At CDR-Life, we’re inspiring the next generation of scientists. Our team visited Neue Schule Zürich to share career paths, teamwork and the science behind our work. We loved meeting future female scientists!

Heading to Milan for BIO-Europe Spring! Our Chief Business Officer @Sarah Holland will share insights on the future of T cell engagers in cancer and autoimmune disease treatment—plus what’s ahead for our innovative M-gager® platform. Let’s connect! #BIOEuropeSpring
#TCellEngagers

CDR-Life completes fifth milestone and is recruiting patients for Phase 2 study of BI 771716 This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

Thank you Modern Retina for covering the progress of our collaboration w Boehringer Ingelheim. We’ve reached our 5th milestone as BI 771716, our antibody fragment technology, advances into Ph 2 trials for geographic atrophy. Patient enrollment is underway!

www.modernretina.com/view/cdr-lif...

With licensed technology developed by CDR-Life, Boehringer Ingleheim advances BI 771716, an antibody fragment-based treatment for geographic atrophy (leading cause of vision loss), to Phase 2 clinical trials. Learn more bit.ly/3Djv5eC

Proud to have our CBO @SarahHolland chair the Pharma Dealmakers Panel at #Sachs_ELSF alongside leaders from @Novartis, @Roche, @GSK, @Sanofi & @Secarna discussing the future of biotech partnerships